Tue, May 9, 2023

Yatin Suneja Maintained (BTAI) at Strong Buy with Decreased Target to $46 on, May 9th, 2023

Yatin Suneja of Guggenheim, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $50 to $46 on, May 9th, 2023.

Yatin has made no other calls on BTAI in the last 4 months.



There are 4 other peers that have a rating on BTAI. Out of the 4 peers that are also analyzing BTAI, 2 agree with Yatin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Chris Howerton of "Jefferies" Downgraded from Strong Buy to Hold and Increased Target to $22 on, Friday, March 10th, 2023
  • Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Increased Target to $26 on, Thursday, January 26th, 2023


These are the ratings of the 2 analyists that currently disagree with Yatin


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $66 on, Tuesday, March 21st, 2023
  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Increased Target to $38 on, Wednesday, February 8th, 2023